🚀 VC round data is live in beta, check it out!
Galectin Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Galectin Therapeutics and similar public comparables like Agenus, Heidelberg Pharma, Immunic, Tiziana Life Sciences and more.
Galectin Therapeutics Overview
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Founded
2001
HQ
Employees
15
Website
Sectors
Financials (LTM)
EV
$270M
Galectin Therapeutics Financials
Galectin Therapeutics reported last 12-month revenue of — and negative EBITDA of ($20M).
In the same LTM period, Galectin Therapeutics generated — in gross profit, ($20M) in EBITDA losses, and had net loss of ($28M).
Revenue (LTM)
Galectin Therapeutics P&L
In the most recent fiscal year, Galectin Therapeutics reported revenue of — and EBITDA of ($20M).
Galectin Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($20M) | XXX | ($20M) | XXX | XXX | XXX |
| Net Profit | ($28M) | XXX | ($31M) | XXX | XXX | XXX |
| Net Debt | — | — | $116M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Galectin Therapeutics Stock Performance
Galectin Therapeutics has current market cap of $151M, and enterprise value of $270M.
Market Cap Evolution
Galectin Therapeutics' stock price is $2.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $270M | $151M | -5.0% | XXX | XXX | XXX | $-0.47 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGalectin Therapeutics Valuation Multiples
Galectin Therapeutics trades at (13.2x) EV/EBITDA.
EV / Revenue (LTM)
Galectin Therapeutics Financial Valuation Multiples
As of April 11, 2026, Galectin Therapeutics has market cap of $151M and EV of $270M.
Equity research analysts estimate Galectin Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Galectin Therapeutics has a P/E ratio of (5.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $151M | XXX | $151M | XXX | XXX | XXX |
| EV (current) | $270M | XXX | $270M | XXX | XXX | XXX |
| EV/EBITDA | (13.2x) | XXX | (13.4x) | XXX | XXX | XXX |
| EV/EBIT | (13.2x) | XXX | (13.4x) | XXX | XXX | XXX |
| P/E | (5.4x) | XXX | (4.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (11.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Galectin Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Galectin Therapeutics Margins & Growth Rates
Galectin Therapeutics' revenue in the last fiscal year grew by —.
Galectin Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.3M for the same period.
Galectin Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 7% | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Galectin Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Agenus | XXX | XXX | XXX | XXX | XXX | XXX |
| Heidelberg Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunic | XXX | XXX | XXX | XXX | XXX | XXX |
| Tiziana Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Curatis Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Galectin Therapeutics M&A Activity
Galectin Therapeutics acquired XXX companies to date.
Last acquisition by Galectin Therapeutics was on XXXXXXXX, XXXXX. Galectin Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Galectin Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGalectin Therapeutics Investment Activity
Galectin Therapeutics invested in XXX companies to date.
Galectin Therapeutics made its latest investment on XXXXXXXX, XXXXX. Galectin Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Galectin Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Galectin Therapeutics
| When was Galectin Therapeutics founded? | Galectin Therapeutics was founded in 2001. |
| Where is Galectin Therapeutics headquartered? | Galectin Therapeutics is headquartered in United States. |
| How many employees does Galectin Therapeutics have? | As of today, Galectin Therapeutics has over 15 employees. |
| Who is the CEO of Galectin Therapeutics? | Galectin Therapeutics' CEO is Joel Lewis. |
| Is Galectin Therapeutics publicly listed? | Yes, Galectin Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Galectin Therapeutics? | Galectin Therapeutics trades under GALT ticker. |
| When did Galectin Therapeutics go public? | Galectin Therapeutics went public in 2002. |
| Who are competitors of Galectin Therapeutics? | Galectin Therapeutics main competitors are Agenus, Heidelberg Pharma, Immunic, Tiziana Life Sciences. |
| What is the current market cap of Galectin Therapeutics? | Galectin Therapeutics' current market cap is $151M. |
| Is Galectin Therapeutics profitable? | No, Galectin Therapeutics is not profitable. |
| What is the current EBITDA of Galectin Therapeutics? | Galectin Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Galectin Therapeutics? | Current EBITDA multiple of Galectin Therapeutics is (13.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.